文献速递冠心病

急诊科心肌梗死0/1小时路径安全性与有效性的国际阶梯楔形整群随机对照试验

Safety and efficacy of the 0/1 h pathway for myocardial infarction in the emergency department: an international, pragmatic, stepped-wedge, cluster-randomised, controlled trial.
PubMed 文献 · Lancet · 2026-08-29

结果显示0/1小时路径30天死亡或新发1型心肌梗死复合终点满足非劣效性,但急诊科留滞时间未缩短。

要点

  • 两组急诊科留滞时间中位数均为309分钟,0/1小时路径未改善急诊周转。
  • 单独实施0/1小时路径不应被期望改善急诊科吞吐量。

核心结论

  • 0/1小时路径达到预设的30天复合安全终点非劣效性标准,但相比0/3小时路径未缩短急诊科留滞时间。
  • 在此背景下,单独实施0/1小时路径不应被期望改善急诊科吞吐量。

研究设计与样本

  • 使用0/3小时路径的医院随机分配至6个月(早期实施)或12个月(晚期实施)后实施0/1小时路径。

关键数值与推荐

  • 共同主要安全终点为30天内全因死亡或新发1型心肌梗死复合终点。
  • 共同主要疗效终点为急诊科留滞时间。

临床怎么用

  • 对急诊疑似心肌梗死患者,0/1小时高敏肌钙蛋白路径在30天安全性方面不劣于0/3小时路径。
  • 不应仅靠实施0/1小时路径来缩短急诊科留滞时间或改善周转。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The evaluation of patients with suspected myocardial infarction relies on serial measurements of high-sensitivity cardiac troponin. We aimed to evaluate the safety and efficacy of implementing the guideline-recommended 0/1 h pathway, compared with a 0/3 h pathway, in hospitals that had not yet adopted the newer strategy. METHODS: PRESC1SE-MI was an international, pragmatic, stepped-wedge, cluster-randomised, controlled, masked-endpoint trial at 19 hospitals in ten countries. The study included consecutive adults presenting to the emergency department with acute non-traumatic chest discomfort and suspected myocardial infarction. Hospitals using a 0/3 h pathway (blood draws at 0 h and 3 h) as standard care were randomly allocated to implement the 0/1 h pathway (blood draws at 0 h and 1 h) after 6 months (early implementation) or 12 months (late implementation). The trial was designed to test the non-inferiority of the 0/1 h pathway for safety and its superiority for efficacy. The non-inferiority margin was set at an odds ratio of 1·3. Analyses were done in the full analysis set. The coprimary safety outcome was a composite of death from any cause or new type 1 myocardial infarction within 30 days, and the coprimary efficacy outcome was emergency department length of stay. This trial is registered with ClinicalTrials.gov, NCT05649384, and is active but no longer enrolling. FINDINGS: Between Dec 1, 2020, and Dec 31, 2024, 71 983 consecutive patient presentations were screened, of which 67 624 (93·9%) met the eligibility criteria and comprised the full analysis set. Median age was 59 years (IQR 46-73); 29 954 (44·3%) patient presentations were in female patients and 37 670 (55·7%) were in male patients. 13 753 (22·2%) of 62 060 patient presentations with available data were in patients with known coronary artery disease, and 5855 (8·7%) patient presentations had an adjudicated index diagnosis of myocardial infarction. Overall, 36 464 patient presentations were managed with a 0/3 h pathway and 31 160 with the 0/1 h pathway. Death from any cause or new type 1 myocardial infarction occurred in 454 (1·2%) patient presentations in the 0/3 h group and in 341 (1·1%) patient presentations in the 0/1 h group (adjusted odds ratio 0·93 [95% CI 0·77-1·13]; pnon-inferiority=0·0004). The median emergency department length of stay was 309 min (IQR 203-470) in the 0/3 h pathway and 309 min (207-474) in the 0/1 h pathway (ratio of adjusted median times 1·00 [95% CI 0·97-1·02]; two-sided p=0·65). INTERPRETATION: Implementation of the 0/1 h pathway met the prespecified non-inferiority criterion for the 30-day composite safety outcome but did not shorten emergency department length of stay compared with the 0/3 h pathway. In this setting, implementation of the 0/1 h pathway alone should therefore not be expected to improve emergency department throughput. FUNDING: Swiss National Science Foundation, Swiss Heart Foundation, University Hospital Basel, University of Basel, Foundation for Cardiovascular Research Basel, Fondazione Ricerca Molinette, Idorsia, and Roche.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Boeddinghaus, Bima, Crisanti, et al. Safety and efficacy of the 0/1 h pathway for myocardial infarction in the emergency department: an international, pragmatic, stepped-wedge, cluster-randomised, controlled trial. Lancet. 2026. PMID: 42667934. doi:10.1016/S0140-6736(26)01654-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。